Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991925 | 0.85 | CHRM1 (0.67) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4402050 | 0.82 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL2996511 | 0.82 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL2993157 | 0.82 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL3411560 | 0.79 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL2997074 | 0.79 | CHRM1 (0.64) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL13243458 | 0.79 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL2992842 | 0.77 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL3003287 | 0.77 | CHRM1 (0.88) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL2993333 | 0.77 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | claimed |
| EP-2035412-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007142585-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | claimed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2035412-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142585-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM2 2/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.